Peptide Library

Human study PLS-00127

Serum levels of immunoreactive thymosin alpha 1 and thymosin beta 4 in large cohorts of healthy adults.

Cross-sectional study · 681 participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Serum levels of immunoreactive thymosin alpha 1 and thymosin beta 4 in large cohorts of healthy adults.primary · Thymus · 1992-02-01 · PMID 1566283

Design and participants

Design
Cross-sectional study
Population
Healthy adults aged 18 to 101 years, analyzed by race, sex and age
Conditions
Healthy volunteers (reference serum levels)
Planned enrollment (registry)
Not reported
Enrolled
681
Randomized
Not reported
Completed follow-up
Not reported
Funding
Publication types list U.S. Government (P.H.S.) and non-U.S. Government research support; no specific funders are named.

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Authors report reference serum ranges for immunoreactive thymosin alpha 1 and beta 4 in healthy adults. Beta 4 did not differ by race or sex but trended slightly upward with age. They suggest the data can serve as a reference for clinical studies and drug kinetics.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Endogenous serum levels were measured; no thymosin beta 4 was given, so the study gives no information on treatment effects or safety.
    • abstract only: Only the abstract is available. Methods, recruitment, setting and funding details are not reported.
    • inappropriate population: Healthy adults without dry eye disease or any treated condition, unlike the claim populations.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 1566283, abstract (sentences 5-7) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 1566283, abstract (sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 1566283, citation (publication types) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 1566283, abstract (sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 1566283, abstract (sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 1566283, abstract (sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).